Autopsy report · NCT00927459

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Potential for immune stimulation to interfere with further dose escalation.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 7 months before it stopped.
23 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: Arbutus Biopharma Corporation
Sponsor type: Industry
Conditions: Hypercholesterolemia
Interventions: PRO-040201; Placebo
Participants: 23
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.